Thursday, January 14, 2016

Antiretroviral Therapy for HIV/AIDS in Claims Data from Statutory Health Insurance Funds in Germany

The objective of this study is to determine the number of patients who receive anti-retroviral medicinal products (ARMs) and to assess the frequency of prescriptions depending on age, gender and treatment regimen by evaluating German statutory health insurance data. 

We analysed a number of databases of several million customers of various nationwide statutory sickness funds and extrapolated the results to the overall population of the statutory health insurance. The number of HIV-positive patients with ARMs varied considerably between the statutory sickness funds analysed. 
  • The number of patients with HIV diagnosis receiving ARMs that are exclusively approved for HIV increased from about 
    • 23,262 in 2008 to 
    • 30,200 in 2010. 
  • For ARMs labelled for both, HIV and HIV/chronic hepatitis B, indications, we calculated about 34,032 patients for the year 2011. 
  • In about 24.2% of the cases with HIV-only and HIV plus HIV/chronic hepatitis B-approved ARMs no HIV-diagnosis was documented. 
  • Patients in this group were significantly younger and more often female as compared to patients with documented HIV diagnosis who received prescriptions of ARMs. 
  • 16.5% of the patients received treatment within the label for chronic hepatitis B. 
  • In 7.7% of the patients ARMs were used off-label for prophylaxis (10.0%), for hepatitis (65.0%) or for unknown reasons (25.0%). 
  • Hence, the number of people under ARMs was estimated to be below the 44,000 patients calculated for statutory sickness funds patients on the basis of prescription data in 2011. 
  • According to our analysis only 39,000 of those could have a documented HIV diagnosis

Below:  Für die gesetzliche Krankenversicherung adjustiert hochgerechnete Alters- und Geschlechtsverteilung für Patienten mit dokumentierter Diagnose und ARM-Verordnungen. Krankenkassen B im Jahr 2011 



Below:  Verordnungshäufigkeit der ARM in Abhängigkeit von der HIV-Diagnose in Krankenkassendaten B. Anteile eingelöster Verordnungen in 1, in 2-3 oder in allen 4 Quartalen



Full article (in German) at:   http://goo.gl/3dMpBT

1Janssen-Cilag GmbH, Abteilung Health Economics, Neuss, Deutschland. Electronic address: jtomeczk@its.jnj.com.
2Janssen-Cilag GmbH, Abteilung Health Economics, Neuss, Deutschland; Institut für Volkswirtschaftslehre, Universität Wien, Österreich.
3Klinik für Immunologie und Rheumatologie, Zentrum Innere Medizin, Medizinische Hochschule Hannover, Hannover, Deutschland.
 2015;109(8):594-604. doi: 10.1016/j.zefq.2014.09.002. Epub 2014 Nov 29.






No comments:

Post a Comment